Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) 2022 revenue was $1.7 million, an increase of 80% compared to $930,000 in 2021.
Q4 Financial Highlights
-
Revenues for the fourth quarter of 2022 were $660,000, an increase of 112% compared to $311,000 in the same period the previous year.
-
Gross profit was $296,000 compared to $44,000 in the same period the previous year.
-
Net loss: Net loss for the fourth quarter of 2022 was $3.8 million, in comparison to a net loss of $8.1 million in the same period in the previous year.
FY 2022 Financial Highlights
-
Gross profit for the full year 2022 was $766,000 compared to $163,000 in 2021.
-
Net loss for the full year 2022 was $29.8 million, in comparison to a loss of $30.4 million for 2021.
-
Approximately $35 million in consolidated cash, cash …